Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted

This article was originally published in The Tan Sheet

Executive Summary

NVE Pharmaceuticals has received only 40 adverse event reports related to its ephedra-containing dietary supplements, the firm tells Sen. Richard Durbin (D-Ill.) in an Oct. 21 letter
Advertisement

Related Content

NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
Mandatory AE Information Requirements Needed For CAERS Filings – AHPA
Ephedra Weight-Loss Claims “Inappropriate,” FDA’s Crawford Says
NVE Pharmaceuticals N.J. Plant Stung In FDA Yellow Jacket Investigation
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records

Topics

Advertisement
UsernamePublicRestriction

Register

PS094703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel